Voice outcomes after concurrent chemoradiotherapy for advanced nonlaryngeal head and neck cancer: a prospective study.

V Paleri, P Carding, S Chatterjee, C Kelly, JA Wilson, A Welch, M Drinnan

Research output: Contribution to journalArticlepeer-review

Abstract

Background
The voice impact of treatment for nonlaryngeal head and neck primary sites remains unknown.

Methods
We conducted a prospective study of a consecutive sample of patients undergoing chemoradiation for nonlaryngeal head and neck cancer. The Voice Symptom Scale (VoiSS) was completed, and voice recordings were made at 3 time-points.

Results
Of 42 recruited patients, 34 completed the measures before and in the early posttreatment phase (mean 16.5 weeks), while 21 patients were assessed at the final time-point (mean, 20.4 months). VoiSS scores showed statistically significant progressive deterioration in the total score (p = .02) and impairment subscale (p < .0001) through to the final assessment. Acoustic measures and perceptual ratings deteriorated significantly (p < .001) in the early posttreatment weeks and improved at the final assessment, but not to the baseline. Interrater agreement was excellent for expert measures.

Conclusion
To the best of our knowledge, this is the first prospective study to show that chemoradiation therapy for nonlaryngeal head and neck cancer has a significant effect on the patients' self-reported voice quality, even in the long term.
Original languageEnglish
Pages (from-to)1747-1752
JournalHead and Neck
Volume34
Issue number12
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Dive into the research topics of 'Voice outcomes after concurrent chemoradiotherapy for advanced nonlaryngeal head and neck cancer: a prospective study.'. Together they form a unique fingerprint.

Cite this